Mutation analysis of factor VIII in Korean patients with severe hemophilia A

被引:7
|
作者
You, Chur-Woo [5 ]
Son, Hee-Sook [5 ]
Kim, Hee Jin [4 ]
Woo, Eui-Jeon [3 ]
Kim, Soon-Ae [2 ]
Baik, Haing-Woon [1 ]
机构
[1] Eulji Univ, Sch Med, Dept Biochem & Mol Biol, Taejon 301832, South Korea
[2] Eulji Univ, Sch Med, Dept Pharmacol, Taejon 301832, South Korea
[3] Korea Res Inst Biosci & Biotechnol, Translat Res Ctr, Taejon, South Korea
[4] Sungkyunkwan Univ, Sch Med, Dept Lab Med, Seoul, South Korea
[5] Eulji Univ, Sch Med, Dept Pediat, Taejon 301832, South Korea
关键词
Severe hemophilia A; Korean; Factor VIII; Mutation; INHIBITOR DEVELOPMENT; INVERSION HOTSPOT; MOLECULAR-BASIS; GENE; IDENTIFICATION; SITE; POLYMORPHISMS; RECOMBINANT; DIAGNOSIS; RESIDUES;
D O I
10.1007/s12185-010-0593-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hemophilia A is an X-linked recessive disorder caused by mutations of the factor VIII gene. The mutation spectrum has been reported in various populations, but not in Koreans. Mutation analysis of the factor VIII gene was performed in 22 unrelated Korean patients with severe hemophilia A. We extracted genomic DNA from their blood, and assessed intron inversions, deletions, and point mutations by direct DNA sequencing. A multiplex ligation-dependent probe amplification gene dosage assay was also performed to identify exon deletions. Disease-causing mutations were identified in all patients, of which four cases were previously unreported. Seven intron 22 inversions, nine point mutations (6 nonsense mutations and 3 missense mutations), and four small rearrangements were identified. One multi-exon deletion and one 5'-donor splicing site mutation were also observed. Four novel mutations (one small deletion, one multiple exon deletion, one missense, and one splice site mutation) were detected, and point mutations were predominant (40.9%), followed by intron 22 inversions (31.8%). Further studies are required in order to establish a solid conclusion regarding the prevalence of various mutations in the Korean population.
引用
收藏
页码:784 / 791
页数:8
相关论文
共 50 条
  • [31] Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A
    Roth, DA
    Tawa, NE
    O'Brien, JM
    Treco, DA
    Selden, RF
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (23): : 1735 - 1742
  • [32] Major disorganization of factor VIII gene as a cause of severe hemophilia A in Indian patients
    Shetty, S
    Ghosh, K
    Mohanty, D
    AMERICAN JOURNAL OF HEMATOLOGY, 2004, 76 (01) : 96 - 96
  • [33] Kinetics of factor VIII: C inhibitors and treatment response in severe hemophilia A patients
    Luna-Zaizar, H.
    Esparza-Flores, M. A.
    Lopez-Guido, B.
    Aguilar-Lopez, L. B.
    Cortes Alvarez, C. R.
    Jaloma-Cruz, A. R.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2009, 31 (06) : 673 - 682
  • [34] INVERSIONS OF THE FACTOR-VIII GENE IN SWEDISH PATIENTS WITH SEVERE HEMOPHILIA-A
    LJUNG, R
    SJORIN, E
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1995, 54 (05) : 310 - 313
  • [35] Hemodialysis in a patient with severe hemophilia A and factor VIII inhibitor
    Gopalakrishnan, Natarajan
    Usha, Thiruvengadam
    Thopalan, Balasubramaniyan
    Dhanapriya, Jeyachandran
    Dineshkumar, Thanigachalam
    Thirumalvalavan, Kaliaperumal
    Sakthirajan, Ramanathan
    HEMODIALYSIS INTERNATIONAL, 2016, 20 (04) : E11 - E13
  • [36] Factor VIII Products and Inhibitor Development in Severe Hemophilia A
    Gouw, Samantha C.
    van der Bom, Johanna G.
    Ljung, Rolf
    Escuriola, Carmen
    Cid, Ana R.
    Claeyssens-Donadel, Segolene
    van Geet, Christel
    Kenet, Gili
    Makipernaa, Anne
    Molinari, Angelo Claudio
    Muntean, Wolfgang
    Kobelt, Rainer
    Rivard, George
    Santagostino, Elena
    Thomas, Angela
    van den Berg, H. Marijke
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (03): : 231 - 239
  • [37] Factor VIII Products and Inhibitors in Severe Hemophilia A REPLY
    van den Berg, H. Marijke
    Gouw, Samantha C.
    van der Bom, Johanna G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (15): : 1457 - 1457
  • [38] Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A
    Repesse, Yohann
    Costa, Catherine
    Palla, Roberta
    Moshai, Elika Farrokhi
    Borel-Derlon, Annie
    D'Oiron, Roseline
    Rothschild, Chantal
    El-Beshlawy, Amal
    Elalfy, Mohsen
    Ramanan, Vijay
    Eshghi, Peyman
    Oldenburg, Johannes
    Pavlova, Anna
    Rosendaal, Frits R.
    Peyvandi, Flora
    Kaveri, Srinivas V.
    Lacroix-Desmazes, Sebastien
    HAEMATOLOGICA, 2019, 104 (08) : E369 - E372
  • [39] Factor VIII gene (F8) mutation and inhibitor development in non-severe hemophilia A
    De Groot-Eckhardt, C. L.
    Van Velzen, A. S.
    Peters, M.
    Peerlinck, K.
    Oldenburg, J.
    Santagostino, E.
    Astermark, J.
    Van Heerde, W. L.
    Hermans, C.
    Morfini, M.
    Castaman, G.
    Haya, S.
    McRae, S.
    Reitter-Pfoertner, S. E.
    Kamphuisen, P. W.
    Van der Bom, J. G.
    Fijnvandraat, K. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 33 - 33
  • [40] Effect of immune system polymorphisms on factor VIII inhibitor development in severe hemophilia a patients
    Bandinelli, E.
    Rosset, C.
    Agostini, D.
    Vieira, I.
    Kappel, D.
    Gorziza, R.
    Botton, M.
    Salzano, F.
    HAEMOPHILIA, 2012, 18 : 88 - 88